MTHFD2 and lung carcinoma: Moreover, the role of high expression MTHFD2 has been well studied in breast cancer [8–11], acute myeloid leukemia [12–14], lymphoma [15], glioma [16–21], hepatocellular cancer [22], pancreatic cancer [23], renal cell carcinoma [24, 25], colorectal cancer [26–28], lung cancer [29–35], head and neck squamous cell cancer [36, 37], gastric cancer [38], esophageal cancer [39, 40], bladder cancer [41], prostate cancer [42], ovarian cancer [43], and other cancers [44–46].